Appropriateness of antiepileptic drug level monitoring.

OBJECTIVES To develop explicit, reliable appropriateness criteria for antiepileptic drug level monitoring and to assess the appropriateness of monitoring in one tertiary care institution. DESIGN Appropriateness criteria derived from the literature and through expert opinion were used to evaluate a stratified random sample of antiepileptic drug level determinations obtained from chart review. SETTING Tertiary care center performing more than 10,000 antiepileptic drug level determinations per year. PATIENTS A total of 330 inpatients in whom antiepileptic drug levels were measured a total of 855 times. METHODS Drug levels were assessed at least 200 times for each of four antiepileptic drugs (phenytoin, carbamazepine, phenobarbital, and valproic acid). MAIN OUTCOME MEASURES The proportion of antiepileptic drug levels with an appropriate indication and, of those, the proportion sampled appropriately. RESULTS Overall, 27% (95% confidence interval, 24% to 30%) of levels had an appropriate indication. Interrater agreement for appropriateness was substantial (kappa = 0.61). There was no significant difference in the appropriateness rate among the four drugs (range, 25% to 29%). Of the 624 antiepileptic drug level determinations considered inappropriate (73%), only four (0.6%) were more than 20% higher than the upper limit of normal, and none of the four patients had clinical signs of drug toxicity. A median of six levels (range, one through 69) was determined per patient, and the median interval between level determinations was 24 hours. Of the 27% of level determinations with an appropriate indication, 51% were sampled correctly, resulting in an overall appropriateness rate of 14%. CONCLUSIONS Only 27% of antiepileptic drug level determinations had an appropriate indication, and half of these were not sampled correctly. Routine daily monitoring without pharmacological justification accounted for most of the inappropriate drug level determinations. Efforts to decrease inappropriate monitoring may result in substantial cost reductions without missing important clinical results.

[1]  A. Feinstein,et al.  Clinical Epidemiology: The Architecture of Clinical Research. , 1987 .

[2]  R. Day,et al.  Compliance with Criteria Necessary for Effective Drug Concentration Monitoring , 1990, Therapeutic drug monitoring.

[3]  Jonathan M. Teich,et al.  Potential identifiability and preventability of adverse events using information systems. , 1994, Journal of the American Medical Informatics Association : JAMIA.

[4]  W. B. Taylor,et al.  Phenytoin and postoperative epilepsy. A double-blind study. , 1983, Journal of neurosurgery.

[5]  L. Ried,et al.  Meta-analysis of research on the effect of clinical pharmacokinetics services on therapeutic drug monitoring. , 1989, American journal of hospital pharmacy.

[6]  Rousseau Gama,et al.  ROUTINE DIAGNOSTIC TESTING , 1989, The Lancet.

[7]  M. Brodie,et al.  New Drugs: Practical clinical pharmacology: monitoring drug concentrations and clinical trials , 1988 .

[8]  G. Mcinnes.  The value of therapeutic drug monitoring to the practising physician--an hypothesis in need of testing. , 1989, British journal of clinical pharmacology.

[9]  B. McNeil,et al.  The Chemistry Laboratory: Development of Average, Fixed, and Variable Costs for Incorporation into a Management Control System , 1987, Medical care.

[10]  H. Bussey,et al.  A prospective evaluation of therapeutic drug monitoring. , 1983, Therapeutic drug monitoring.

[11]  Five Years of Anticonvulsant Monitoring on Site at the Epilepsy Clinic , 1993, Therapeutic drug monitoring.

[12]  G D Lundberg,et al.  Perseverance of laboratory test ordering: a syndrome affecting clinicians. , 1983, JAMA.

[13]  T. Tomson,et al.  Epilepsy and Pregnancy: A Prospective Study of Seizure Control in Relation to Free and Total Plasma Concentrations of Carbamazepine and Phenytoin , 1994, Epilepsia.

[14]  C. Sorkness,et al.  Use of serum drug concentrations in outpatient clinics. , 1985, American journal of hospital pharmacy.

[15]  D. E. Rogers,et al.  Medical technology -- a different view of the contentious debate over costs. , 1979, The New England journal of medicine.

[16]  M. Levine,et al.  Evaluation of Serum Phenytoin Monitoring in an Acute Care Setting , 1988, Therapeutic drug monitoring.

[17]  D. Wing,et al.  The impact of a therapeutic drug monitoring program for phenytoin. , 1989, Therapeutic drug monitoring.

[18]  J M Teich,et al.  Computerized physician order entry and quality of care. , 1994, Quality management in health care.

[19]  W. Theodore.  Rational use of antiepileptic drug levels. , 1992, Pharmacology & therapeutics.

[20]  J. W. A. S. Sander,et al.  IMMEDIATE ANTICONVULSIVE DRUG MONITORING IN MANAGEMENT OF EPILEPSY , 1987, The Lancet.

[21]  N. Laird,et al.  Incidence of Adverse Drug Events and Potential Adverse Drug Events: Implications for Prevention , 1995 .

[22]  S. Vožeh.  Cost-Effectiveness of Therapeutic Drug Monitoring , 1987, Clinical pharmacokinetics.

[23]  C. Knott,et al.  Therapeutic Drug Monitoring in Pregnancy Rationale and Current Status , 1990 .

[24]  E. F. Ullman,et al.  "Homogeneous" enzyme immunoassay. A new immunochemical technique. , 1972, Biochemical and biophysical research communications.

[25]  R. Beardsley,et al.  Anticonvulsant Serum Levels Are Useful Only If the Physician Appropriately Uses Them: An Assessment of the Impact of Providing Serum Level Data to Physicians , 1983, Epilepsia.

[26]  McDonald Cj,et al.  Guidelines You Can Follow and Can Trust: An Ideal and an Example , 1994 .

[27]  A. Troupin.  Diagnostic decision. The measurement of anticonvulsant agent levels. , 1984, Annals of internal medicine.

[28]  I. Choonara,et al.  Therapeutic Drug Monitoring of Anticonvulsants , 1990, Clinical pharmacokinetics.

[29]  B. Levin,et al.  Effect of pharmacist intervention on the use of serum drug assays. , 1981, American journal of hospital pharmacy.

[30]  J. Fleiss.  Statistical methods for rates and proportions , 1974 .

[31]  D. Chadwick.  Overuse of monitoring of blood concentrations of antiepileptic drugs. , 1987, British medical journal.